Personalis (PSNL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
12 May, 2026Opening remarks and agenda
CEO welcomed attendees, introduced board and management, and outlined the virtual meeting format with Q&A opportunities.
Formal business included three proposals: director elections, auditor ratification, and executive compensation approval.
Board and executive committee updates
Board members and executive team were introduced, including external legal counsel and independent auditors.
Shareholder proposals
No stockholder nominations for director were submitted; nominations were closed.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Personalis
- Clinical test volumes soared 258% year-over-year as Medicare coverage expanded, despite revenue decline.PSNL
Q1 20268 May 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, all board-recommended.PSNLProxy filing2 Apr 2026
- Proxy covers director elections, auditor ratification, pay-for-performance, and key related party deals.PSNLProxy filing2 Apr 2026
- Clinical test volume soared nearly 400% in 2025, with 2026 revenue guided to $78–$80 million.PSNLQ4 202527 Feb 2026
- Ultra-sensitive ctDNA testing detects cancer recurrence and therapy response earlier than current methods.PSNLStatus Update3 Feb 2026
- Q2 revenue up 35% year-over-year, guidance raised, net loss narrowed, but risks remain.PSNLQ2 20242 Feb 2026
- Q3 revenue up 41% year-over-year, biopharma surges, and cash runway extends to 2027.PSNLQ3 202416 Jan 2026
- 14M shares from a $50M private placement registered for resale; no proceeds to the company.PSNLRegistration Filing16 Dec 2025
- 3.5M shares registered for resale after $17.7M private placement with Tempus AI, Inc.PSNLRegistration Filing16 Dec 2025